PROMOGRAN™ Matrix Wound Dressing

Products described on this website (and associated product information), may not be available for sale in all markets as a result of local regulatory requirements. For information regarding product availability in your market, please contact your local Acelity/KCI representative here.

A Clinically Proven Combination

PROMOGRAN™ Matrix is comprised of a sterile, freeze dried composite of 45% oxidized regenerated cellulose (ORC) and 55% collagen.

 

Optimum Wound Environment

PROMOGRAN™ Matrix, when covered with a semi-occlusive or non-occlusive dressing maintains an optimal wound healing environment. This environment is conducive to granulation tissue formation, epithelization and rapid wound healing. 

 

Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Healthcare providers should review the product User Manual, Safety Information and/or Instructions for Use prior to application.

 

 


  • Overview
  • How it Works
  • Indications & Applications
  • Evidence & Outcomes
  • Ordering

    Overview

Clinically Proven

PROMOGRAN™ Matrix COLLAGEN & ORC is supported by a body of clinical evidence, including 13 RCT's data.1-13

Several RCT's have demonstrated that PROMOGRAN™ Matrix Dressing achieved superior results versus standard of care in chronic wounds.

Economic Value

 

PROMOGRAN™  Matrix was more cost-effective per patient over 6 weeks of treatment as compared to standard care (Control).3

KCI Advanced Wound Dressings Advanced Dressing Technology

 

PROMOGRAN™ Matrix Family, the only dressings with collagen and Oxidized Regenerated Cellulose (ORC).

How it Works

  • ABOUT
  • SPECIFICATIONS
  • MATERIALS FOR DOWNLOAD

Maintains an optimum wound healing environment

In the presence of exudate, PROMOGRAN™  Matrix transforms into a soft, conformable, biodegradable gel. This allows contact with all areas of the wound.
 
Economic Value

A retrospective study analyzing cost-effectiveness in the management of neuropathic DFU (n=40), showed that wound Management with PROMOGRAN™  Matrix was more cost-effective per patient over 6 weeks of treatment as compared to standard care (Control)3.

Product Description

PROMOGRAN™ Matrix is a sterile, freeze dried composite of oxidized regenerated cellulose (ORC) and collagen. In the presence of exudate the PROMOGRAN™ Matrix transforms into a soft conformable, biodegradabile gel; this allows contact with all areas of the wound. Saline solution should be used to hydrate PROMOGRAN™ Matrix prior to application in dry wounds.

 

PROMOGRAN-Matrix-Specs.png

Indications & Applications

  • INDICATIONS
  • APPLICATIONS

Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Healthcare providers should review the product User Manual, Safety Information and/or Instructions for Use prior to application.

 

Indications for use

PROMOGRAN™ Matrix is intended for the management of exuding wounds, including:

  • Diabetic ulcers
  • Venous ulcers
  • Pressure ulcers
  • Ulcers caused by mixed vascular etiologies
  • Full-thickness and partial thickness wounds
  • Donor sites and other bleeding surface wounds
  • Abrasions
  • Traumatic wounds healing by secondary intention
  • Dehisced surgical wounds
  • PROMOGRAN™ Matrix can be used under compression therapy with healthcare professional supervision
Wound Bed Preparation
Prepare wound bed per your standard wound care protocol and debride when necessary. Wound bed should be clear of any visual signs of infection. 

 

Application

  • For optimal effect, apply PROMOGRAN™ Matrix directly to the whole wound bed.
  • For a wound with low or no exudate apply PROMOGRAN™ Matrix and hydrate with saline solution. This will initiate the transformation of the PROMOGRAN™ Matrix into a gel.
  • After hydration, through exposure to wound exudate or saline, the PROMOGRAN™ Matrix gel will intimately come into contact with the wound surface.
  • The biodegradable PROMOGRAN™ Matrix gel is naturally absorbed into the body over time.
  • In order to maintain a moist wound healing environment PROMOGRAN™ Matrix must be covered with a semi-occlusive dressing (e.g. BIOCLUSIVE™  Plus Transparent Film Dressing, TIELLE™  Hydropolymer Foam Dressings or TIELLE™  Plus Hydropolymer Adhesive Dressing) or a non-occlusive secondary dressing and fixed to the skin with a non-irritating tape.
  • After initial application, reapply PROMOGRAN™ Matrix to the wound up to every 72 hours depending upon the amount of exudate. It is not necessary to remove any residual PROMOGRAN™ Matrix during dressing changes. 

 

 

Evidence & Outcomes

 

The efficacy of PROMOGRAN™ Matrix is supported by clinical evidence, including 13 published RCTs.1-13Acelity Clinical Evidence is a resource for healthcare professionals to explore clinical, and review articles discussing the use of Acelity™  products. 

Clinical Evidence

Additional summary of evidence and outcomes.
TITLE A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Veves A, et al.
TITLE Wound conditioning of a deep tissue defect including exposed bone after tumour excision using PROMOGRAN* Matrix, a protease-modulating matrix.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2005
AUTHORS Tausche AK, et al.
TITLE Collagen ORC rebalances the wound environment
View Abstract on PubMed
STUDY TYPE All levels
DATE 2003
AUTHORS Cullen B, et al.
TITLE The healing properties of Promogran in venous leg ulcers.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Vin F, et al.
TITLE Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose /collagen matrix treatment in pressure sore ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2015
AUTHORS Smeets, et al.
TITLE Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2006
AUTHORS Lobmann R, et al.
TITLE Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Cullen B, et al.
TITLE Effect of oxidized regenerated cellulose/collagen matrix on proteases in wound exudate of patients with diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Ulrich, et al.
TITLE Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Kakagia DD, et al. 
TITLE Some effects of a topical collagen-based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: preliminary observations
View Abstract on PubMed
STUDY TYPE All levels
DATE 2005
AUTHORS Wollina U, et al.
TITLE Modulation of the chronic wound environment; an in vitro evaluation of advanced wound therapies
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Cullen B, et al.
TITLE The benefits of oxidized regenerated cellulose (ORC) for wound healing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2010
AUTHORS Cullen B, et al.
TITLE The role of oxidized regenerated cellulose / collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Hart, et al.
TITLE Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Lazaro-Martinez, et al.
TITLE Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2013
AUTHORS Gottrup F, et al.
TITLE Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration
View Abstract on PubMed
STUDY TYPE All levels
DATE 2008
AUTHORS Smeets, et al.
TITLE Expression of Matric-Metalloproteases in the Fluid of Chronic Diabetic Foot Wounds Treated with a Protease Absorbent Dressing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2011
AUTHORS Motzkau M, et al.
TITLE Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Ghatnekar O, et al.

 

Ordering

To order any of the products listed below, please contact your KCI representative or call your local KCI Office. Click here to contact us.

Contact Us

  • PROMOGRAN™ Matrix Wound Dressing

    PRODUCT PRODUCT CODE   dressings per box
     
    FS-380x380-actisorb-silver-front.jpg

    PROMOGRAN™ Matrix Wound Dressing

    4.34 sq. in Hexagon

     
     
     PG004 Box of 40 (4 Cartons of 10)
    HCPCS Code A6021
     
    FS-380x380-actisorb-silver-front.jpg

    PROMOGRAN™ Matrix Wound Dressing

    19.1 sq. in Hexagon


     PG019 Box of 40 (4 Cartons of 10)
    HCPCS Code A6022